15 / 36
Cadmigde WLCC 2016
ALTA:
PFS Randomized Dose Evaluation Brigatinib
No
reduction
>0-25%
reduction
>25-50%
reduction
>50-75%
reduction
>75-100%
reduction
90 mg once daily
13
20
35
20
13
90 mg
180 mg
once daily
7
23
29
19
22
% patients with
reduction in
target lesions: